A global contract development and manufacturing organization focused on drug-device combination products. The company operates across multiple sites in the U.S. and the U.K., including a U.K.

Hovione today announced the launch of its Rapid Proof of Concept Study for the development of dry powder inhalation (DPI) products. Building on Hovione´s well established DPI development capability, ...

CRDMOs offer a continuum of services from early discovery to clinical manufacturing, addressing solubility and stability challenges in NCE development. Advanced technologies like spray drying and ...

HANGZHOU, China, March 17, 2025 /PRNewswire/ -- Chance Pharmaceuticals ("Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhalation ...

Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced that it has successfully dosed the ...

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its ...

Scientists have successfully tested the use of machine learning models to guide the design of long-acting injectable drug formulations. The potential for machine learning algorithms to accelerate drug ...

AUSTIN, Texas, April 23, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet ...

To optimize the final formulation for a drug, it must meet many criteria beyond producing a safe and effective product. For example, it must be stable and amenable to various manufacturing steps, such ...

Researchers at the University of Toronto say they have successfully tested the use of machine learning models to guide the design of long-acting injectable drug formulations. The potential for machine ...

NanoViricides Inc (NYSE:NNVC) has developed oral gummies formulations of its Pan-Coronavirus COVID-19 Drug Candidate NV-CoV-2 to benefit non-hospitalized patients. What Happened: NanoViricides ...